Biotech Massively Bid Up Before Opening Bell

Biotech Massively Bid Up Before Opening Bell

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, January 9, 2024

A North Carolina-based biotech firm is turning heads so far Tuesday morning after it was announced a strategic transaction with TG Therapeutics Inc. (Nasdaq:TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer, according to the release.

Traders were extremely excited about the news as shares of Precision BioSciences Inc. (Nasdaq:DTIL) got aggressively bid up right before the opening bell, with traders currently willing to buy shares of the micro cap at $0.4563/share (+14.65% implied open for sellers) at the time of writing. It should be an exciting session for this biotech!

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm.


Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares of Dual-Listed Lithium Firm Up After Announcing Quarterly Results
Firm Holds Strategic Conversation on Possible Acquisition in Short-Term Rental Market
Small Cap Massively Bid Following Key Q1 Earnings Beat
Most Popular
FREE Newsletter


Back to Top